普洛药业（000739）2025年中报简析：净利润同比下降9.89%，盈利能力上升

Core Viewpoint - Prolo Pharmaceutical's recent financial report indicates a decline in revenue and net profit for the first half of 2025, with a notable increase in profitability metrics such as gross margin and net margin [1] Financial Performance - Total revenue for the first half of 2025 was 5.444 billion yuan, a decrease of 15.31% year-on-year [1] - Net profit attributable to shareholders was 563 million yuan, down 9.89% year-on-year [1] - In Q2 2025, total revenue was 2.714 billion yuan, a decline of 15.98% year-on-year, with net profit at 315 million yuan, down 17.48% year-on-year [1] - Gross margin increased to 25.73%, up 4.18% year-on-year, while net margin rose to 10.34%, an increase of 6.44% year-on-year [1] Cost and Expenses - Total selling, administrative, and financial expenses amounted to 443 million yuan, representing 8.13% of revenue, an increase of 11.64% year-on-year [1] - The company's cash flow from operating activities decreased significantly by 58.48% due to a reduction in contract liabilities and accounts payable [4] Asset and Liabilities - Cash and cash equivalents decreased, with a net increase of -79.13% attributed to reduced cash flow from operating activities [4] - The company reported a rise in interest-bearing liabilities to 1.208 billion yuan, up from 1.048 billion yuan year-on-year [1] Investment and Returns - The company's return on invested capital (ROIC) was reported at 13.02%, indicating strong capital returns historically [3] - The average expected net profit for 2025 is projected at 1.052 billion yuan, with an average earnings per share of 0.91 yuan [5] Fund Holdings - The largest fund holding Prolo Pharmaceutical is Dachen Rui Xiang Mixed A, which increased its position to 14.2896 million shares [6] - Notable fund managers, including Xu Yan from Dachen Fund, have increased their stakes in the company [6] Business Outlook - The CDMO business is expected to grow significantly, with projections indicating a revenue target of 6 to 7 billion yuan by 2030, with a balanced focus on the US and Chinese markets [7]